Identifying actionable components in castration–resistant prostate cancer (CRPC) is critical for the development of effective treatments. Here, the authors show that the inhibition of the redox-protective protein TRX1 decreases the growth of CRPC cells through the regulation of ROS levels, p53 and androgen receptor expression.
- Govindi J. Samaranayake
- Clara I. Troccoli
- Priyamvada Rai
